Martin Maron to Heart Failure
This is a "connection" page, showing publications Martin Maron has written about Heart Failure.
Connection Strength
7.815
-
Maron BJ, Rowin EJ, Maron MS. Advances in the Management of Hypertrophic Cardiomyopathy Leading to Low Disease-Related Mortality in 2023. Am J Cardiol. 2024 02 01; 212S:S77-S82.
Score: 0.495
-
Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, Garcia-Pavia P, Lakdawala NK, Nagueh SF, Rader F, Tower-Rader A, Turer AT, Coats C, Fifer MA, Owens A, Solomon SD, Watkins H, Barriales-Villa R, Kramer CM, Wong TC, Paige SL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham T. Phase 2 Study of Aficamten in Patients?With Obstructive Hypertrophic?Cardiomyopathy. J Am Coll Cardiol. 2023 01 03; 81(1):34-45.
Score: 0.459
-
Rowin EJ, Cooper C, Carrick RT, Tsoi M, Maron BJ, Maron MS. Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2022 09 15; 179:70-73.
Score: 0.444
-
Rowin EJ, Maron MS. Refining Endpoint Measures in Clinical Trials for Hypertrophic Cardiomyopathy: The Emerging Role of Patient-Reported Outcomes. JACC Heart Fail. 2022 08; 10(8):540-542.
Score: 0.441
-
Maron BJ, Maron MS. Jeff Zucker Says Hypertrophic Cardiomyopathy is a Curable Disease: A Patient's Perspective. Am J Cardiol. 2022 06 01; 172:154-156.
Score: 0.441
-
Rowin EJ, Maron BJ, Wells S, Burrows A, Firely C, Koethe B, Patel AR, Maron MS. Usefulness of Global Longitudinal Strain to Predict Heart Failure Progression in Patients With Nonobstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2021 07 15; 151:86-92.
Score: 0.415
-
Rowin EJ, Maron BJ, Maron MS. Reply: The LVAD in the Management of Advanced Heart?Failure Due to Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020 10 20; 76(16):1913.
Score: 0.389
-
Maron BJ, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here? Am J Med. 2020 08; 133(8):886-888.
Score: 0.388
-
Rowin EJ, Romashko M, Testani JM, Koethe BC, Saxena D, Udelson JE, Maron BJ, Maron MS. Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy. J Card Fail. 2019 08; 25(8):690-692.
Score: 0.358
-
Maron MS, Udelson JE, Rowin EJ, Maron BJ. Reply: Atrial Fibrillation in Hypertrophic Cardiomyopathy. JACC Heart Fail. 2018 09; 6(9):807-808.
Score: 0.340
-
Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical Spectrum and Management?of?Heart Failure in?Hypertrophic?Cardiomyopathy. JACC Heart Fail. 2018 05; 6(5):353-363.
Score: 0.331
-
Maron BJ, Maron MS. Nonobstructive Hypertrophic Cardiomyopathy: Overlooked But Not Forgotten. Mayo Clin Proc. 2016 Mar; 91(3):277-8.
Score: 0.286
-
Rowin EJ, Maron BJ, Kiernan MS, Casey SA, Feldman DS, Hryniewicz KM, Chan RH, Harris KM, Udelson JE, DeNofrio D, Roberts WC, Maron MS. Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant. Circ Heart Fail. 2014 Nov; 7(6):967-75.
Score: 0.258
-
Maron BJ, Maron MS. The 25-year genetic era in hypertrophic cardiomyopathy: revisited. Circ Cardiovasc Genet. 2014 Aug; 7(4):401-4.
Score: 0.256
-
Olivotto I, Maron BJ, Tomberli B, Appelbaum E, Salton C, Haas TS, Gibson CM, Nistri S, Servettini E, Chan RH, Udelson JE, Lesser JR, Cecchi F, Manning WJ, Maron MS. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013 Jul 30; 62(5):449-57.
Score: 0.235
-
Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013 Feb 05; 127(5):585-93.
Score: 0.229
-
Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008 Sep; 1(3):184-91.
Score: 0.168
-
Campain J, Griskowitz C, Newlands C, Claggett BL, Kulac IJ, McGinnis S, Giverts I, Moreno F, Minasian A, Prasad C, Rupert L, Landsteiner I, Iskenderian N, Coats CJ, Lee MMY, Maron MS, Owens AT, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Malhotra R, Lewis GD. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. Circulation. 2025 Oct 07; 152(14):990-1002.
Score: 0.138
-
Maron MS, Zenovich AG, Casey SA, Link MS, Udelson JE, Aeppli DM, Maron BJ. Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy. Am J Cardiol. 2005 Jun 01; 95(11):1329-33.
Score: 0.136
-
Bonaventura J, Rowin EJ, Chan RH, Chin MT, Puchnerova V, Polakova E, Macek M, Votypka P, Batorsky R, Perera G, Koethe B, Veselka J, Maron BJ, Maron MS. Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2024 May 21; 13(10):e033565.
Score: 0.126
-
Coats CJ, Maron MS, Abraham TP, Olivotto I, Lee MMY, Arad M, Cardim N, Ma CS, Choudhury L, D?ngen HD, Garcia-Pavia P, Hag?ge AA, Lewis GD, Michels M, Oreziak A, Owens AT, Tfelt-Hansen J, Veselka J, Watkins HC, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Wohltman A, Masri A. Exercise Capacity in Patients With?Obstructive Hypertrophic?Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design. JACC Heart Fail. 2024 01; 12(1):199-215.
Score: 0.122
-
Owens AT, Masri A, Abraham TP, Choudhury L, Rader F, Symanski JD, Turer AT, Wong TC, Tower-Rader A, Coats CJ, Fifer MA, Olivotto I, Solomon SD, Watkins HC, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn R, Wohltman A, Maron MS. Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3. J Card Fail. 2023 11; 29(11):1576-1582.
Score: 0.119
-
Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003 Jan 23; 348(4):295-303.
Score: 0.115
-
Maron BA, Kleiner DE, Arons E, Wertheim BM, Sharma NS, Haley KJ, Samokhin AO, Rowin EJ, Maron MS, Rosing DR, Maron BJ. Evidence of Advanced Pulmonary Vascular Remodeling in Obstructive Hypertrophic Cardiomyopathy With Pulmonary Hypertension. Chest. 2023 03; 163(3):678-686.
Score: 0.113
-
Maron BJ, Rowin EJ, Maron MS. After 60 Years Hypertrophic Cardiomyopathy is Finally Recognized as a Contemporary Treatable Disease With Low Mortality and Morbidity, But is This Paradigm Under-Recognized in the Literature? Am J Cardiol. 2021 03 01; 142:136-137.
Score: 0.099
-
Rowin EJ, Maron BJ, Carrick RT, Patel PP, Koethe B, Wells S, Maron MS. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. J Am Coll Cardiol. 2020 06 23; 75(24):3033-3043.
Score: 0.096
-
Ahmad F, McNally EM, Ackerman MJ, Baty LC, Day SM, Kullo IJ, Madueme PC, Maron MS, Martinez MW, Salberg L, Taylor MR, Wilcox JE. Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards: A Scientific Statement From the American Heart Association. Circ Genom Precis Med. 2019 06; 12(6):e000054.
Score: 0.089
-
Maron BJ, Rowin EJ, Maron MS. Global Burden of Hypertrophic?Cardiomyopathy. JACC Heart Fail. 2018 05; 6(5):376-378.
Score: 0.083
-
Rowin EJ, Maron MS, Chan RH, Hausvater A, Wang W, Rastegar H, Maron BJ. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017 Dec 15; 120(12):2256-2264.
Score: 0.080
-
Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, Maron BJ, Maron MS, Maron BA. Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circ Heart Fail. 2017 Apr; 10(4):e003689.
Score: 0.077
-
Kalra A, Harris KM, Maron BA, Maron MS, Garberich RF, Haas TS, Lesser JR, Maron BJ. Relation of Doppler Tissue Imaging Parameters With Heart Failure Progression in Hypertrophic Cardiomyopathy. Am J Cardiol. 2016 06 01; 117(11):1808-14.
Score: 0.072
-
Sharkey SW, Pink VR, Lesser JR, Garberich RF, Maron MS, Maron BJ. Clinical Profile of Patients With High-Risk Tako-Tsubo Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):765-72.
Score: 0.068
-
Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS. Hypertrophic Cardiomyopathy in?Adulthood Associated With Low?Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol. 2015 May 12; 65(18):1915-28.
Score: 0.068
-
Maron BJ, Weiner HL, Maron MS, Roberts WC. Surviving malignant hypertrophic cardiomyopathy with all major complications in a single patient. Am J Cardiol. 2015 Feb 01; 115(3):402-4.
Score: 0.065
-
Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012 Feb 01; 14:13.
Score: 0.054
-
Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011 Jan; 4(1):98-108.
Score: 0.050
-
Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS, Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun. 2021 02 08; 12(1):873.
Score: 0.025
-
Shirani J, Aurshiya R, Elshaikh A, Olenchock SA, Rowin EJ, Maron MS, Maron BJ. Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices. Am J Cardiol. 2021 03 01; 142:130-135.
Score: 0.025
-
Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017 Dec 19; 136(25):2420-2436.
Score: 0.020
-
Maron BJ, Rowin EJ, Maron MS, Braunwald E. Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored ? Until Now. Am J Med. 2017 02; 130(2):119-123.
Score: 0.019
-
Sharkey SW, Windenburg DC, Lesser JR, Maron MS, Hauser RG, Lesser JN, Haas TS, Hodges JS, Maron BJ. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010 Jan 26; 55(4):333-41.
Score: 0.012
-
Maron BJ, Maron MS, Wigle ED, Braunwald E. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009 Jul 14; 54(3):191-200.
Score: 0.011